The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 2, 2014, Pages 149-158

  Pötsch, Mareike S ^a   Tschirner, Anika ^a   Palus, Sandra ^a   von Haehling, Stephan ^a   Doehner, Wolfram ^a   Beadle, John ^b   Coats, Andrew J S ^c,d   Anker, Stefan D ^a   Springer, Jochen ^a,e,f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PSIOXUS THERAPEUTICS LTD   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Anabolic catabolic transforming agent (ACTA); Espindolol; Fat mass; Muscle mass; Sarcopenia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CASPASE 3; ESPINDOLOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC 3 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGY; AUTOPSY; BIOSYNTHESIS; BODY COMPOSITION; CATABOLISM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRY MASS; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTENSOR DIGITORUM LONGUS MUSCLE; FAT MASS; FLUID INTAKE; FOOD INTAKE; GASTROCNEMIUS MUSCLE; HEART FUNCTION; LEAN BODY WEIGHT; LOCOMOTION; MALE; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE; UPREGULATION; WATER CONTENT; WEIGHT GAIN; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84902492098     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0125-7     Document Type: Article

References (43)

1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127: 990S.
2. Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol. 1977;43: 1001.
3. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970;19: 653.
4. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57: M772.
5. Frontera WR, Hughes VA, Lutz KJ, Evans WJ. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol. 1991;71: 644.
6. Brooks SV, Faulkner JA. Skeletal muscle weakness in old age: underlying mechanisms. Med Sci Sports Exerc. 1994;26: 432.
7. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159: 413.
8. Visser M et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci. 2005;60: 324.
9. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52: 80.
10. Clark BC, Manini TM. Functional consequences of sarcopenia and dynapenia in the elderly. Curr Opin Clin Nutr Metab Care. 2010;13: 271.
11. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010;1: 9.
12. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1: 129.
13. Stewart Coats AJ et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2: 201.
14. Palus S, Akashi Y, von Haehling S, Anker SD, Springer J. The influence of age and sex on disease development in a novel animal model of cardiac cachexia. Int J Cardiol. 2009;133: 388.
15. Schmidt K et al. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle. 2011;2: 105.
16. Akashi YJ et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol. 2009;137: 267.
17. Baumgarten A et al. TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. Int J Cardiol. 2013;168: 1447.
18. Springer J et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. International journal of cancer Journal international du cancer. 2012;131: 2187.
19. Lang T et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int. 2010;21: 543.
20. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr. 2000;54 Suppl 3: S48.
21. Morley JE. Sarcopenia: diagnosis and treatment. J Nutr Health Aging. 2008;12: 452.
22. Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging. 2010;5: 217.
23. Han HQ, Mitch WE. Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr Opin Support Palliat Care. 2011;5: 334.
24. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011;2: 143.
25. Ratkevicius A et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci. 2011;66: 620.
26. Murphy KT et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. Faseb J. 2010;24: 4433.
27. Zhou X et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142: 531.
28. Busquets S et al. Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology letters. 2012;3: 185.
29. Clavel S et al. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat tibialis anterior muscle. Mech Ageing Dev. 2006;127: 794.
30. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci. 2007;62: 1407.
31. Chung L, Ng YC. Age-related alterations in expression of apoptosis regulatory proteins and heat shock proteins in rat skeletal muscle. Biochim Biophys Acta. 2006;1762: 103.
32. Whitman SA, Wacker MJ, Richmond SR, Godard MP. Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age. Pflugers Arch. 2005;450: 437.
33. Teng BT, Pei XM, Tam EW, Benzie IF, Siu PM. Opposing responses of apoptosis and autophagy to moderate compression in skeletal muscle. Acta Physiol (Oxf). 2011;201(239).
34. Kim DH et al. Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J Pharmacol Exp Ther. 2008;325: 833.
35. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89: 2583.
36. Glass DJ. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol. 2010;346: 267.
37. Parkington JD, LeBrasseur NK, Siebert AP, Fielding RA. Contraction-mediated mTOR, p70S6k, and ERK1/2 phosphorylation in aged skeletal muscle. J Appl Physiol. 2004;97: 243.
38. Simone C et al. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet. 2004;36: 738.
39. Suelves M, Lluis F, Ruiz V, Nebreda AR, Munoz-Canoves P. Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes. Embo J. 2004;23: 365.
40. Rahnert JA, Luo Q, Balog EM, Sokoloff AJ, Burkholder TJ. Changes in growth-related kinases in head, neck and limb muscles with age. Exp Gerontol. 2011;46: 282.
41. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378: 704.
42. Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004;47: 11.
43. Saxena PR, Heiligers JP, Villalon CM, Ferrari MD. Effects of tertatolol, a beta-adrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. Eur J Pharmacol. 1992;220: 79.